Diagnostic Value of Serum Biomarkers for Invasive Aspergillosis in Haematologic Patients.
Galactomannan Ag Platelia
MycoGENIE PCR
Wako Beta-D-Glucan
biomarkers
galactomannan Ag VirClia
haematologic patients
invasive aspergillosis
Journal
Journal of fungi (Basel, Switzerland)
ISSN: 2309-608X
Titre abrégé: J Fungi (Basel)
Pays: Switzerland
ID NLM: 101671827
Informations de publication
Date de publication:
20 Sep 2024
20 Sep 2024
Historique:
received:
13
08
2024
revised:
17
09
2024
accepted:
18
09
2024
medline:
27
9
2024
pubmed:
27
9
2024
entrez:
27
9
2024
Statut:
epublish
Résumé
Invasive aspergillosis (IA) is a significant cause of morbidity and mortality in patients with haematological malignancies. Accurate diagnosis of IA is challenging due to non-specific symptoms and the impact of antifungal prophylaxis on biomarker sensitivity. This retrospective study evaluated the diagnostic performance of three serum biomarkers: Most patients diagnosed with proven or probable IA were acute myeloid leukaemia or myelodysplastic syndrome patients receiving mould-active antifungal prophylaxis or treatment (71%). VirClia demonstrated high sensitivity (100%) for detecting IA, with a specificity of 83%. Wako BDG and MycoGENIE PCR showed lower sensitivities for IA (57% and 64%, respectively). MycoGENIE PCR detected Accurate diagnosis of IA remains challenging, especially in patients who have received mould-active antifungal treatment. VirClia showed comparable performance to Platelia, suggesting its potential for routine use. However, Wako BDG and MycoGENIE PCR results were less favourable in our study cohort. Nevertheless, MycoGENIE PCR detected two probable co-infections with
Sections du résumé
BACKGROUND
BACKGROUND
Invasive aspergillosis (IA) is a significant cause of morbidity and mortality in patients with haematological malignancies. Accurate diagnosis of IA is challenging due to non-specific symptoms and the impact of antifungal prophylaxis on biomarker sensitivity.
METHODS
METHODS
This retrospective study evaluated the diagnostic performance of three serum biomarkers:
RESULTS
RESULTS
Most patients diagnosed with proven or probable IA were acute myeloid leukaemia or myelodysplastic syndrome patients receiving mould-active antifungal prophylaxis or treatment (71%). VirClia demonstrated high sensitivity (100%) for detecting IA, with a specificity of 83%. Wako BDG and MycoGENIE PCR showed lower sensitivities for IA (57% and 64%, respectively). MycoGENIE PCR detected
CONCLUSIONS
CONCLUSIONS
Accurate diagnosis of IA remains challenging, especially in patients who have received mould-active antifungal treatment. VirClia showed comparable performance to Platelia, suggesting its potential for routine use. However, Wako BDG and MycoGENIE PCR results were less favourable in our study cohort. Nevertheless, MycoGENIE PCR detected two probable co-infections with
Identifiants
pubmed: 39330420
pii: jof10090661
doi: 10.3390/jof10090661
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : FONDATION MONT-GODINNE
ID : FMG-BR-2023-008